Lumos Diagnostics Holdings Ltd
Lumos Diagnostics Holdings Limited is an Australia-based company specializes in point-of-care (POC) diagnostic test technology to help healthcare professionals diagnose and manage medical conditions.
The business
Lumos Diagnostics Holdings Limited is an Australia-based company specializes in point-of-care (POC) diagnostic test technology to help healthcare professionals diagnose and manage medical conditions. The Company offers customized assay development and manufacturing services for POC tests and digital reader platforms. It also directly develops, manufactures, and commercializes Lumos-branded POC tests that target infectious and inflammatory diseases. Its Products offering is based on developing and commercializing its own suite of POC diagnostic products which are primarily focused on the diagnosis and management of infectious diseases. These include FebriDx, a POC test for detecting and differentiating viral and bacterial respiratory infections, and ViraDx, a threein-one point-of-care test for influenza A, influenza B and COVID-19. The Company manages the full development program for POC assays.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Lumos Diagnostics Expands FebriDx Rollout Across Priority US Urgent Care Accounts
Lumos Diagnostics expands FebriDx rollout to 430 US urgent care sites across top accounts, targeting 2.6 million ARI visits annually—rapid expansion under way.
Lumos Diagnostics Achieves BARDA Paediatric Study Milestone, Secures US$720k Payment
Lumos Diagnostics hits BARDA Milestone 6, secures US$720k non-dilutive payment as FebriDx paediatric study advances toward FDA submission and wider US TAM.
Lumos Diagnostics Secures Full US Medicare Reimbursement Recognition for FebriDx Test
Lumos Diagnostics (ASX: LDX) has achieved complete US Medicare reimbursement recognition for its FebriDx point-of-care diagnostic test, securing coverage from all seven Medicare Administrative Contractors.
Lumos Diagnostics secures US government funding to develop groundbreaking FebriDx test
Lumos Diagnostics (ASX: LDX) has received significant US financial backing for its development of unique point-of-care diagnostic test technology. Lumos has been awarded approximately $4.3 million by a division of the US government’s health division to support a planned study and regulatory submission for the company’s FebriDx bacterial/non-bacterial test. FebriDx is designed to assess whether […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.